임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

19건 표시

1상모집 중· Healthy Subjects
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
리드: 유한양행
상세 →NCT07470125
1상모집 중· Obesity & Overweight
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
리드: 대웅제약
상세 →NCT07539415
1상모집 중· Cancer
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
리드: 대웅제약
상세 →NCT07371104
1상모집 중· Healthy
To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers
리드: JW중외제약
상세 →NCT07514780
1상모집 중· Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
리드: 삼성바이오에피스
상세 →NCT07524348
1상모집 중· Atopic Dermatitis
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
리드: 종근당
상세 →NCT07358156
1상모집 중· Healthy Volunteers
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
리드: 대웅제약
상세 →NCT07267221
1상모집 중· Psoriasis
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
리드: 종근당
상세 →NCT07258745
1상모집 중· Obesity
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
리드: 한미약품
상세 →NCT07219589
1상모집 중· Healthy Volunteers
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
리드: 대웅제약
상세 →NCT07260851
1상모집 중· Advanced Solid Tumors
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
리드: 종근당
상세 →NCT07215637
1상모집 중· Healthy Subjects
PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers
리드: 대웅제약
상세 →NCT07144176
1상모집 중· Healthy
To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers
리드: JW중외제약
상세 →NCT06703710
1상모집 중· Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
리드: 한미약품 · 협력: 머크(MSD)
상세 →NCT06724016
1상모집 중· Autoimmune Diseases
Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
리드: 대웅제약
상세 →NCT06736587
1상모집 중· Sanfilippo Syndrome Type A
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
리드: GC녹십자
상세 →NCT06567769
1상모집 중· Healthy Participants
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
리드: 유한양행
상세 →NCT06517914
1상모집 중· Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
리드: 한미약품 · 협력: 머크(MSD)
상세 →NCT06234397
1상모집 중· Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
리드: 한미약품
상세 →NCT05598151

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.